Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase-4 inhibitor

被引：0
|
作者：
Maita, Hiroki [1 ]
Kobayashi, Tadashi [2 ]
Akimoto, Takashi [2 ]
Osawa, Hiroshi [2 ]
Kato, Hiroyuki [1 ,2 ,3 ]
机构：
[1] Hirosaki Univ, Dev Community Healthcare, Grad Sch Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan
[2] Hirosaki Univ, Dept Gen Med, Sch Med Hosp, Aomori, Japan
[3] Hirosaki Univ, Gen Med, Grad Sch Med, Aomori, Japan
来源：
JOURNAL OF GENERAL AND FAMILY MEDICINE | 2022年 / 23卷 / 02期
关键词：
blister; dipeptidyl peptidase-4 inhibitor; edema; sitagliptin;
D O I：
10.1002/jgf2.502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：124 / 125
页数：2
相关论文
共 50 条
  • [31] Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
    Herman, Gary A.
    Bergman, Arthur
    Yi, Bingming
    Kipnes, Mark
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 1939 - 1947
  • [32] Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
    Harada, Masaru
    Yoneda, Akitoshi
    Haruyama, Sanehito
    Yabuki, Kei
    Honma, Yuichi
    Hiura, Masaaki
    Shibata, Michihiko
    Matsuoka, Hidehiko
    Uchiwa, Yasuhiro
    INTERNAL MEDICINE, 2017, 56 (18) : 2471 - 2474
  • [33] Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Tatosian, Daniel A.
    Guo, Ying
    Schaeffer, Andrea K.
    Gaibu, Natalia
    Popa, Serghei
    Stoch, Aubrey
    Langdon, Ronald B.
    Kauh, Eunkyung A.
    DIABETES THERAPY, 2013, 4 (02) : 431 - 442
  • [34] Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Daniel A. Tatosian
    Ying Guo
    Andrea K. Schaeffer
    Natalia Gaibu
    Serghei Popa
    Aubrey Stoch
    Ronald B. Langdon
    Eunkyung A. Kauh
    Diabetes Therapy, 2013, 4 : 431 - 442
  • [35] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes
    Aso, Yoshimasa
    Jojima, T.
    Iijima, T.
    Suzuki, K.
    Terasawa, T.
    Fukushima, M.
    Momobayashi, A.
    Hara, K.
    Takebayashi, K.
    Kasai, K.
    Inukai, T.
    ENDOCRINE, 2015, 50 (03) : 659 - 664
  • [36] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes
    Yoshimasa Aso
    T. Jojima
    T. Iijima
    K. Suzuki
    T. Terasawa
    M. Fukushima
    A. Momobayashi
    K. Hara
    K. Takebayashi
    K. Kasai
    T. Inukai
    Endocrine, 2015, 50 : 659 - 664
  • [37] Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
    Roy, Ayan
    Sahoo, Jayaprakash
    Narayanan, Niya
    Merugu, Chandhana
    Kamalanathan, Sadishkumar
    Naik, Dukhabandhu
    WORLD JOURNAL OF DIABETES, 2021, 12 (09) : 1426 - 1441
  • [38] Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
    Furuta, Shinji
    Tamura, Miyuki
    Hirooka, Hiroko
    Mizuno, Yukie
    Miyoshi, Mika
    Furuta, Yoshiyuki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2013, 38 (02) : 87 - 96
  • [39] Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats
    Rofaeil, Remon Roshdy
    Ahmed, Sabreen Mahmoud
    Bahaa, Haitham Ahmed
    Mahran, Ahmad
    Welson, Nermeen N.
    Abdelzaher, Walaa Yehia
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 25 (11)
  • [40] Modelling the Sitagliptin Effect on Dipeptidyl Peptidase-4 Activity in Adults with Haematological Malignancies After Umbilical Cord Blood Haematopoietic Cell Transplantation
    Nieves Vélez de Mendizábal
    Robert M. Strother
    Sherif S. Farag
    Hal E. Broxmeyer
    Steven Messina-Graham
    Shripad D. Chitnis
    Robert R. Bies
    Clinical Pharmacokinetics, 2014, 53 : 247 - 259
12345